Literature DB >> 24328844

The reliability and validity of the Iranian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: the EORTC QLQ-BM22.

Mir S Yekaninejad1, Ahmad Ahmadzadeh, Seyed H Mosavi, Mohsen Saffari, Amir H Pakpour, Fatemeh Tolooei, Edward Chow, Andrew Bottomley.   

Abstract

The aim of the present study was to evaluate the psychometric properties of the measure among a sample of Iranian patients with bone metastases. One hundred and seventy-seven patients with bone metastases undergoing various treatments were recruited from Imam Khomeini Hospital in Tehran to participate in the study. The coefficient alpha affirmed internal consistency reliability of the Quality of Life Questionnaire for patients with Bone Metastases (QLQ-BM22). This measure discriminated well between subgroups of the patients based on performance status and responding to treatment. Confirmatory factor analysis confirmed the factorial validity of the four hypothesized QLQ-BM22 scales. Patients in this study had a similar interpretation of the items on the QLQ-BM22 regardless of gender. All scales of the QLQ-BM22 were sensitive to change after treatment over a month's follow-up, with the exception of psychosocial aspects. The Persian version of the EORTC QLQ-BM22 was highly reliable and is valid for use among patients with bone metastases who are undergoing various treatment regimes.

Entities:  

Mesh:

Year:  2013        PMID: 24328844     DOI: 10.1586/14737167.2014.864559

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  1 in total

1.  Validation of the Chinese version of EORTC QLQ-BM22 in patients with bone metastases.

Authors:  Lei Zhang; Yan-Jun Su; Jia-Yue Chen; Zhi-Chao Liao; Zhi-Qin Luo; Shu-Min Xie; Jing Zhang; Yun-Shou Lin; Hui Guo; Wei-Lin Sun; Begüm Pekbay; Adam R Miller; Le Luo; Yu-Hua Rui; Mo-Han Li; Chang-Li Wang
Journal:  Support Care Cancer       Date:  2015-08-06       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.